Q32 Bio reported earnings of -$ 0.26 per QTTB share on Nov 4, 2026, falling short of analysts' expectations by
| Report Date | Nov 4, 2026 |
|---|---|
| Forecasted EPS | -$ 0.33 |
| Earnings Per Share (Surprise) | -$ 0.26 (+$ 0.06669) |
| Last Year's EPS | $ 0.3425 |
| EPS YoY Change |
Out of the last 41 earnings reporting periods, Q32 Bio beat analysts’ expectations 14 times and fell short of expectations 9 time(s). Q32 Bio reported earnings per share of -$ 0.26 in the last report surpassing an estimated EPS of -$ 0.33 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 4, 2026 | -$ 0.33 | -$ 0.26 | -$ 0.60 | |
| Aug 5, 2026 | -$ 0.46 | -$ 0.44 | -$ 0.78 | |
| May 5, 2026 | -$ 0.68 | -$ 0.54 | -$ 0.90 | |
| Mar 10, 2026 | -$ 0.85 | $ 3.65 | -$ 1.16 | |
| Nov 13, 2025 | -$ 1.39 | -$ 0.60 | -$ 1.46 | |
| Aug 6, 2025 | -$ 1.14 | -$ 0.78 | -$ 1.42 | |
| May 8, 2025 | -$ 1.23 | -$ 0.90 | -$ 14.95 | |
| Mar 11, 2025 | -$ 1.25 | -$ 1.16 | -$ 0.28 | |
| Nov 7, 2024 | -$ 1.41 | -$ 1.46 | -$ 10.26 | |
| Aug 8, 2024 | -$ 1.00 | -$ 1.42 | -$ 10.98 | |
| May 9, 2024 | -$ 1.42 | -$ 14.95 | -$ 9.00 | |
| Mar 13, 2024 | -$ 0.30 | -$ 0.28 | -$ 9.00 | |
| Nov 14, 2023 | -$ 7.56 | -$ 10.26 | -$ 10.74 | |
| Jul 27, 2023 | -$ 8.55 | -$ 10.98 | -$ 10.62 | |
| May 11, 2023 | -$ 9.54 | -$ 9.00 | -$ 10.57 | |
| Mar 30, 2023 | -$ 9.54 | -$ 9.00 | -$ 9.18 | |
| Dec 30, 2022 | -$ 8.86 | -$ 10.74 | -$ 9.12 | |
| Nov 10, 2022 | -$ 8.21 | -$ 10.62 | $ 28.62 | |
| Sep 29, 2022 | -$ 8.21 | -$ 10.57 | $ 28.65 | |
| Aug 15, 2022 | -$ 9.68 | -$ 9.18 | -$ 10.58 |
Q32 Bio’s stock was trading at $ 8.76 on Nov 3, 2026 a day before the last earnings report was released.Following the release of the earnings report, QTTB’s price increased to $ 8.85 on Nov 5, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 4, 2026 | -$ 0.26 | $ 8.76 | $ 8.85 | |
| Aug 5, 2026 | -$ 0.44 | $ 16.16 | $ 16.20 | |
| May 5, 2026 | -$ 0.54 | $ 5.04 | $ 5.47 | |
| Mar 10, 2026 | $ 3.65 | $ 5.10 | $ 6.91 | |
| Nov 13, 2025 | -$ 0.60 | $ 2.43 | $ 2.16 | |
| Aug 6, 2025 | -$ 0.78 | $ 1.98 | $ 1.79 | |
| May 8, 2025 | -$ 0.90 | $ 1.57 | $ 1.55 | |
| Mar 11, 2025 | -$ 1.16 | $ 2.06 | $ 1.90 | |
| Nov 7, 2024 | -$ 1.46 | $ 48.00 | $ 45.29 | |
| Aug 8, 2024 | -$ 1.42 | $ 40.10 | $ 34.43 | |
| May 9, 2024 | -$ 14.95 | $ 26.28 | $ 27.13 | |
| Mar 13, 2024 | -$ 0.28 | $ 16.16 | $ 16.69 | |
| Nov 14, 2023 | -$ 10.26 | $ 18.54 | $ 15.84 | |
| Jul 27, 2023 | -$ 10.98 | $ 18.54 | $ 23.94 | |
| May 11, 2023 | -$ 9.00 | $ 17.64 | $ 17.68 | |
| Mar 30, 2023 | -$ 9.00 | $ 18.18 | $ 18.54 | |
| Dec 30, 2022 | -$ 10.74 | $ 21.06 | $ 21.60 | |
| Nov 10, 2022 | -$ 10.62 | $ 24.30 | $ 27.00 | |
| Sep 29, 2022 | -$ 10.57 | $ 29.16 | $ 28.98 | |
| Aug 15, 2022 | -$ 9.18 | $ 49.68 | $ 52.02 |
Q32 Bio released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Q32 Bio beat analysts’ expectations during the last earnings period by
